EGFR and neoplasm: In a phase IIB trial comparing afatinib and gefitinib for first-line treatment in common EGFR mutation metastatic adenocarcinoma patients, afatinib demonstrated a significantly higher objective tumor response rate compared to gefitinib (70% vs. 56%) (21).